Hint mode is switched on Switch off
For swift navigation between sections

Infant Bacterial Therapeutics
LEI 2138008KVBXCRJGP6Z26

PDF download

Choose all Reset all
Download Cancel
Organization name
Infant Bacterial Therapeutics AB
Country name
Sweden
Country of registration
Sweden
Industry
Pharmaceutical Preparation and Biotechnology
Public debt
-
Welcome to Cbonds
New to Cbonds? · Take a 90-second tour of the platform.

Discover what you can do with Cbonds

Everything you need for fixed income research and monitoring.

  • 00:23 Coverage
  • 00:40 Bond screener
  • 00:54 Parameters
  • 01:10 Watchlist, Mobile app
  • 01:15 Excel Add-in
Get access Watch full tour

Latest data on

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Get access to the largest financial database

Representative of the company 7 days FREE trial

Professional access to the data

Private investor

Individual access

Quotes

Request sent
Access denied
Send request
Quotes provided by information providers are indicative in nature

Profile

Infant Bacterial Therapeutics AB (IBT) is a clinical-stage pharmaceutical company. It develops drugs influencing the infant microbiome, and thereby prevent or treat rare diseases affecting infants. IBT is developing its drug candidate IBP-9414 to prevent NEC in premature infants. IBP-9414 contains the active substance Lactobacillus reuteri, which is a human bacterial strain naturally present in breast milk.

Awards

Documentation

Stocks

Public debt by currencies

Show more Hide

Codes

  • LEI
    2138008KVBXCRJGP6Z26
  • SIC
    2834 PHARMACEUTICAL PREPARATIONS
  • NACE
    *** ***
  • NAICS
    *** ***
  • Organisationsnummer
    556873-8586
Registration is required to get access.